eCite Digital Repository

Bosentan for the treatment of adult pulmonary hypertension

Citation

Kilpatrick, D and Dwyer, N, Bosentan for the treatment of adult pulmonary hypertension, Future cardiology, 7, (1) pp. 19-37. ISSN 1479-6678 (2011) [Refereed Article]

DOI: doi:10.2217/fca.10.114

Abstract

Pulmonary hypertension is a severe progressive disease with a marked morbidity and a high mortality attributed to right heart failure. Bosentan, a dual endothelin receptor antagonist, is an effective and well-tolerated oral therapy for the management of pulmonary arterial hypertension (PAH; WHO group 1 pulmonary hypertension). Bosentan improves cardiopulmonary hemodynamics, exercise capacity, WHO functional class and quality of life, as well as delaying time to clinical worsening in patients with PAH. This article reviews the role of endothelin-1 in the pathogenesis and progression of PAH, the diagnosis of PAH and the pharmacology of bosentan, and summarizes the current available evidence for the safety and efficacy of bosentan for the treatment of PAH as a monotherapy and combination therapy, as well as its role in the management of other forms of pulmonary hypertension.

Item Details

Item Type:Refereed Article
Research Division:Medical and Health Sciences
Research Group:Cardiorespiratory Medicine and Haematology
Research Field:Cardiology (incl. Cardiovascular Diseases)
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Cardiovascular System and Diseases
Author:Kilpatrick, D (Professor David Kilpatrick)
ID Code:83906
Year Published:2011
Web of Science® Times Cited:6
Deposited By:Medicine (Discipline)
Deposited On:2013-03-27
Last Modified:2017-10-06
Downloads:0

Repository Staff Only: item control page